Last reviewed · How we verify
LINEZOLID
LINEZOLID is a Oxazolidinone Antibacterial [EPC] drug. It is currently FDA-approved (first approved 2000).
Linezolid is a small molecule inhibitor of the bacterial 70S ribosome, classified as an INHIBITOR. It has been studied for various conditions, including Mycobacterium Abscessus Lung Disease, Tuberculosis, and Complicated Skin and Skin Structure Infections, among others.
At a glance
| Generic name | LINEZOLID |
|---|---|
| Drug class | Oxazolidinone Antibacterial [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 2000 |
Approved indications
Common side effects
- Headache
- Diarrhea
- Nausea
- Vomiting
- Dizziness
- Rash
- Anemia
- Taste alteration
- Vaginal moniliasis
- Oral moniliasis
- Abnormal liver function tests
- Fungal infection
Drug interactions
- Monoamine Oxidase Inhibitors (e.g., Linezolid)
- Adrenergic and Serotonergic Agents
Key clinical trials
- Linezolid Plus Standard of Care (NA)
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis (PHASE2)
- Linezolid Tolerance During the BPaL Regimen With Dosage Personalization Based on Therapeutic Drug Monitoring (TDM) During Multidrug-Resistant Tuberculosis Treatment (PHASE4)
- Linezolid for Syphilis Pilot Study (PHASE2)
- Prospective, Randomized, Multicenter Clinical Trial of Bisphosphonates Combined With Vancomycin for the Treatment of Cierny-Mader Type I and III Osteomyelitis (PHASE3)
- Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis (PHASE4)
- A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LINEZOLID CI brief — competitive landscape report
- LINEZOLID updates RSS · CI watch RSS
Frequently asked questions about LINEZOLID
What is LINEZOLID?
What drug class is LINEZOLID in?
When was LINEZOLID approved?
What development phase is LINEZOLID in?
What are the side effects of LINEZOLID?
Related
- Drug class: All Oxazolidinone Antibacterial [EPC] drugs
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing